Media coverage about AveXis (NASDAQ:AVXS) has trended somewhat positive on Tuesday, according to Accern. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AveXis earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.5737099801777 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

A number of research analysts have recently weighed in on the stock. ValuEngine downgraded shares of AveXis from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Bank of America reduced their target price on shares of AveXis from $115.00 to $112.00 and set a “buy” rating for the company in a research report on Friday, November 10th. Royal Bank of Canada increased their target price on shares of AveXis from $92.00 to $97.00 and gave the company a “sector perform” rating in a research report on Friday, November 10th. Chardan Capital reissued a “buy” rating on shares of AveXis in a research report on Thursday, November 2nd. Finally, Zacks Investment Research downgraded shares of AveXis from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and thirteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $110.67.

AveXis (NASDAQ:AVXS) traded down $4.43 on Tuesday, reaching $93.66. 426,606 shares of the company traded hands, compared to its average volume of 425,889. AveXis has a 52 week low of $44.68 and a 52 week high of $108.27.

AveXis (NASDAQ:AVXS) last released its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same period in the prior year, the company earned ($0.87) EPS. analysts predict that AveXis will post -6.23 earnings per share for the current year.

In related news, VP Andrew F. Knudten sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $94.48, for a total value of $188,960.00. Following the completion of the transaction, the vice president now directly owns 7,000 shares of the company’s stock, valued at approximately $661,360. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $97.25, for a total transaction of $173,105.00. Following the completion of the transaction, the vice president now directly owns 1,780 shares of the company’s stock, valued at $173,105. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 52,340 shares of company stock valued at $5,172,298. 18.60% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.watchlistnews.com/avexis-avxs-given-daily-news-sentiment-rating-of-0-08/1760188.html.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Insider Buying and Selling by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.